Research in New Zealand
In New Zealand, the Cystic Fibrosis Association of New Zealand has its own research fund called Share in Life. This fund is available to medical and scientific researchers who wish to study aspects of CF, with a view to clinical application.
The fund is open at all times and applicants should contact the Chief Executive of the CFANZ in the first instance on 0800 65 1122
We also have a close relationship with the Child Health Research Foundation and have co-funded a number of CF projects with them.
For the past three years, the Association has concentrated its funding in the area of Stem Cell Research, through a project at the University of Melbourne, led by Professor Bob Williamson and Dr Faten Zaibek.
We have also partially funded various basic science projects and a number of qualiity of life surveys.
News from the Research World
http://www.rttnews.com/CorpInfo/DisplayWatchList.aspx?Node=B6&page=1472
Pharmaxis' cystic-fibrosis drug meets goal in study Mon May 4, 2009 6:42am EDT
May 4 (Reuters) - Australian pharmaceutical company Pharmaxis Ltd (PXS.AX) (PXSL.O) said its experimental cystic-fibrosis drug, Bronchitol, met the main goal of improving lung function in a late-stage trial. Cystic fibrosis is a genetic disease in which the body produces a thicker-than-normal mucus that clogs the lungs and other organs.
In the trial, more than 300 patients received 400 mg of Bronchitol twice per day for six months, the company said. Lung function improved at week 6 and was sustained through to week 26.
Bronchitol also met the secondary goal of improving lung function in patients who were already being treated for cystic fibrosis with Genentech's Pulmozyme, which was launched in 1994, Pharmaxis said.
Genentech, which was acquired by Roche (ROG.VX) in March, reported 2008 U.S sales of $257 million for Pulmozyme.
Bronchitol has an orphan-drug status in Europe, as well as the United States, and Pharmaxis plans to file for marketing approval later this year. No new products have been approved anywhere in the world for cystic
fibrosis for more than 10 years, Pharmaxis said. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Vinu Pilakkott)
Page Top
